Skip to main content
OpenTrials
Completed

NCT Number: NCT02576002

Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)

To describe the prevalence, incidence and current treatment and procedures patterns in a US pediatric population with PAH in MarketScan database during the period 2010-2013

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension, Pulmonary Cardiovascular Diseases Hypertension Lung Diseases Pulmonary Arterial Hypertension Respiratory Tract Diseases Vascular Diseases

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Boston, Massachusetts, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All PAH patients who were in the MarketScan database and who were under age 18 at some time during the years 2010 through 2013

Exclusion criteria

Not applicable

Treatment and study plan

Assigned pulmonary hypertension medication

Drug

As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators

Primary outcomes

  1. Incidence rate of PAH (pulmonary arterial hypertension)

    Time frame: Retrospective analysis of three year period

  2. Prevalence rate of PAH

    Time frame: Retrospective analysis of three year period

Secondary outcomes

  1. Assigned drug treatment for PAH measured using the MarketScan database

    Time frame: Retrospective analysis of three year period

    Description of pulmonary hypertension-targeted drugs prescribed in the study population and changes during the study period

  2. Diagnostic procedures performed among PAH patients measured using the MarketScan database

    Time frame: Retrospective analysis of three year period

  3. Prevalence of comorbidities among PAH patients

    Time frame: Retrospective analysis of three year period

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Study to Estimate the Incidence and Prevalence and Treatment Patterns of Pediatric Pulmonary Hypertension in the US

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Oct 15, 2015
Registry last updated
Feb 26, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.